Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624877 | 0.90 | DRD2 (0.47) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL20666512 | 0.89 | MAPT (0.50) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL8526813 | 0.84 | DRD2 (0.57) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL27265657 | 0.81 | DRD2 (0.53) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL3245294 | 0.80 | DRD2 (0.49) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL3238417 | 0.80 | DRD2 (0.49) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL23520056 | 0.78 | KDM4E (0.44) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL4627275 | 0.78 | DRD2 (0.37) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL3231505 | 0.78 | DRD2 (0.46) | DRD2DRD4KDM4EMAPTALDH1A1 | |
| SCHEMBL3238840 | 0.77 | DRD2 (0.49) | DRD2DRD4KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2022226349-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2022-10-27 | — | — | WO | disclosed |
| EP-3203840-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-1891063-B1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| EP-0639182-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
| WO-1992018483-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | DRD2 1614/4885DRD4 3506/4885KDM4E 4042/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | DRD2 1425/4885DRD4 3613/4885KDM4E 3918/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | DRD2 4318/4885DRD4 4706/4885KDM4E 1340/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | DRD2 2964/4885DRD4 3686/4885KDM4E 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.